



Docket No.: 2312/2085B (formerly 1440.1027-005)

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Raghuram Kalluri  
Serial No.: 09/543,371  
Filed: April 4, 2000  
Entitled: Anti-Angiogenic Proteins and  
Fragments and Methods of Use Thereof

Examiner: J. Roark  
Group Art Unit: 1644  
Conf. No.: 6148

**CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.10**

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office using Express Mail to Addressee Service under 37 C.F.R. Section 1.10, Express Mail Label No. EL932822271US on this date, September 11, 2002, postage prepaid, in an envelope addressed to U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, Virginia 22202.

Joyce C. Hersh, Ph.D.

Name of Person Mailing Paper

Signature of Person Mailing Paper

U.S. Patent and Trademark Office  
Box Sequence  
P.O. Box 2327  
Arlington, VA 22202

**TRANSMITTAL OF FORMAL DRAWINGS**

In response to the Office Action mailed on March 12, 2002 in the above-referenced patent application, enclosed please find formal drawings of Figures 18A and 18B on two separate sheets.

Acceptance of the formal drawings is respectfully requested.

Respectfully submitted,

Name: Joyce C. Hersh, Ph.D.  
Registration No.: 42,890  
Palmer & Dodge LLP  
111 Huntington Avenue  
Boston, MA 02199-7613  
Tel: 617-239-0100

Date: September 11, 2002

APPROVED BY DRAFTSMAN	O.G. FIG. CLASS	SUBCLASS
-----------------------------	--------------------	----------

Docket/App No.: 1440.1027-005

Title: Anti-Angiogenic Proteins and Fragments and Methods of Use Thereof  
Inventors: Raghuram Kalluri

## FIG. 18A

pET22b(+) forward primer:

5'-CGGGAT CCA GGT TTG AAA GGA AAA CGT-3' (SEQ ID NO:11).

pET22b(+) reverse primer:

5'-CCCAAGCTT TCA GTG TCT TTT CTT CAT-3' (SEQ ID NO:12)

5	10	15	20	25	30	35	40	45
cca	qgt	ttq	aaa	qqa	aaa	cqt	gga	gac
50	55	60	65	70	75	80	85	90
tgg	aca	acg	aga	ggc	ttt	gtc	ttc	acc
95	100	105	110	115	120	125	130	135
gca	att	cct	tca	tgt	cca	gag	ggg	aca
140	145	150	155	160	165	170	175	180
ttt	tct	ttt	ctt	ttt	gta	caa	gga	aat
185	190	195	200	205	210	215	220	225
gac	ctt	gga	act	ctt	ggc	agc	tgc	ctg
230	235	240	245	250	255	260	265	270
cca	tcc	tta	ttc	tgc	aat	gtc	aat	gtt
275	280	285	290	295	300	305	310	315
cga	aat	gat	tat	tca	tac	tgg	ctg	tca
320	325	330	335	340	345	350	355	360
atg	aac	atg	gct	ccc	att	act	ggc	aga
365	370	375	380	385	390	395	400	405
agc	aga	tgc	act	gtt	tgt	gaa	ggt	oct
410	415	420	425	430	435	440	445	450
cac	agc	caa	acc	act	gac	att	cct	cca
455	460	465	470	475	480	485	490	495
tct	ctc	tgg	aaa	gga	ttt	tca	ttc	atc
500	505	510	515	520	525	530	535	540
tct	gag	ggc	acc	ggg	caa	gca	ctg	gcc
545	550	555	560	565	570	575	580	585
gaa	gaa	ttc	cga	gcc	agc	cca	ttt	cta
590	595	600	605	610	615	620	625	630
acg	tgc	aac	tac	tat	tca	aat	tcc	tac
635	640	645	650	655	660	665	670	675
tta	aac	cca	gaa	aga	atg	ttc	aga	aag
680	685	690	695	700	705	710	715	720
aaa	gct	ggg	gaa	tta	gaa	aaa	ata	ata
725	730	735						
<u>atq aaq aaa aqa cac tqa</u>								

(SEQ ID NO:9)

pET22b- $\alpha$ 3(IV) NC1 = nucleotides 4 through 735

Tumstatin 333 = nucleotides 4 through 375

Tumstatin 334 - nucleotide 376 through 735

APPROVED	O.G. FIG.	
BY	CLASS	SUBCLASS
DRAFTSMAN		

Docket/App No.: 1440.1027-005  
 Title: Anti-Angiogenic Proteins and Fragments and Methods of Use Thereof  
 Inventors: Raghuram Kalluri

## FIG. 18B

\*

5	10	15	20	25	30	35	40	45						
PGL	KGK	RGD	SGS	PAT	WTT	RGF	VFT	RHS	QTT	AIP	SCP	EGT	VPL	YSG

  

50	55	60	65	70	75	80	85	90						
FSF	LFV	QGN	QRA	HGQ	DLG	TLG	SCL	QRF	TTM	PFL	FCN	VND	VCN	FAS

  

95	100	105	110	115	120	125	130	135						
RND	YSY	WLS	TPA	LMP	MNM	API	TGR	ALE	PYI	SRC	TVC	EGP	AIA	IAV

  

140	145	150	155	160	165	170	175	180						
HSQ	TTD	IPP	CPH	GWI	SLW	KGF	SFI	MFT	SAG	SEG	TGQ	ALA	SPG	SCL

  

185	190	195	200	205	210	215	220	225						
EEF	RAS	PFL	ECH	GRG	TCN	YYs	NSY	SFW	LAS	LNP	ERM	FRK	PIP	STV

  

230	235	240	245			
KAG	ELE	KII	SRC	QVC	MKK	RH

+(SEQ ID NO:10)

pET22b  $\alpha$ 3(IV) NC1 = residues 2 through 245

Tumstatin 333 = residues 2 through 125

Tumstatin 334 = residues 126 through 245